Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Recent Advances in Drug Delivery and Treatment of Neglected Tropical...
share announcement

Recent Advances in Drug Delivery and Treatment of Neglected Tropical Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2082

Special Issue Editors

Dr. Luiz Felipe Domingues Passero

E-Mail Website
Guest Editor
Institute for Advanced Studies of Ocean, São Paulo State University (UNESP), São Vicente 11350-011, Brazil
Interests: neglected tropical diseases; parasite; bacteria; virus; fungus; oral and local treatment; formulations; dermatological cream; liposome; nanoparticles; immunity
Special Issues, Collections and Topics in MDPI journals
Dr. Dolores R. Serrano

E-Mail Website1 Website2
Guest Editor
Departament of Pharmaceutics and Food Technology, School of Pharmacy, University Complutense, Avenida Complutense, 28040 Madrid, Spain
Interests: nanomedicines; microparticles; sustained-release formulations; liposomes; nanoparticles; drug targeting; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Around 1.6 billion people are affected by neglected tropical diseases (NDTs) whose etiologic agents are related to bacteria, viruses, fungi, and parasites. These diseases frequently occur in tropical countries and in general affect vulnerable people living in close contact with such organisms. Control of NTDs has been considered a real challenge because the life cycles of etiologic agents are complex and involve the participation of different reservoirs and there are no effective prophylactic measures in place.

Chemotherapy for NTD is far from ideal, considering that drugs in use induce serious side effects in patients, the therapeutic activity may be variable for some clinical forms, and the emergence of naturally resistant microorganisms.

This Special Issue is open to articles focused on novel formulations to target NTDs through different administration routes such as oral, topical and parenteral with a special focus on micro and nanomedicines including pharmacokinetics and pharmacodynamics studies.

Dr. Luiz Felipe Domingues Passero
Dr. Dolores R. Serrano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neglected tropical diseases
  • drug targeting
  • microparticulate formulations
  • novel formulations
  • liposomes
  • nanomedicines

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1907 KiB  
Article
First Description of Marinoquinoline Derivatives’ Activity against Toxoplasma gondii
by Luiza Tamie Hirata Diethelm, Amanda Bruno da Silva Bellini Ramos, Giovanna Braga de Lorena, Bruna Inácio Trajano, Rafael Dias do Espírito Santo, Renata Priscila Barros de Menezes, Marcus Tullius Scotti, Fabio Antonio Colombo, Marcos José Marques, Carlos Roque Duarte Correia and Juliana Quero Reimão
Pharmaceutics 2024, 16(2), 262; https://doi.org/10.3390/pharmaceutics16020262 - 10 Feb 2024
Viewed by 899
Abstract
Toxoplasmosis is a globally prevalent zoonotic disease with significant clinical implications, including neurotoxoplasmosis, a leading cause of cerebral lesions in AIDS patients. The current pharmacological treatments for toxoplasmosis face clinical limitations, necessitating the urgent development of new therapeutics. Natural sources have yielded diverse [...] Read more.
Toxoplasmosis is a globally prevalent zoonotic disease with significant clinical implications, including neurotoxoplasmosis, a leading cause of cerebral lesions in AIDS patients. The current pharmacological treatments for toxoplasmosis face clinical limitations, necessitating the urgent development of new therapeutics. Natural sources have yielded diverse bioactive compounds, serving as the foundation for clinically used derivatives. The exploration of marine bacteria-derived natural products has led to marinoquinolines, which feature a pyrroloquinoline core and demonstrate in vitro and in vivo anti-Plasmodium activity. This study investigates the in vitro anti-Toxoplasma gondii potential of six marinoquinoline derivatives. Additionally, it conducts absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions, and evaluates the in vivo efficacy of one selected compound. The compounds displayed half-maximal effective concentration (EC50) values between 1.31 and 3.78 µM and half-maximal cytotoxic concentration (CC50) values ranging from 4.16 to 30.51 µM, resulting in selectivity indices (SI) from 3.18 to 20.85. MQ-1 exhibiting the highest in vitro SI, significantly reduced tachyzoite numbers in the peritoneum of RH-infected Swiss mice when it was orally administered at 12.5 mg/kg/day for eight consecutive days. Also, MQ-1 significantly reduced the cerebral parasite burden in chronically ME49 infected C57BL/6 mice when it was orally administered at 25 mg/kg/day for 10 consecutive days. These findings underscore the promising anti-T. gondii activity of marinoquinolines and their potential as novel therapeutic agents against this disease. Full article
(This article belongs to the Special Issue Recent Advances in Drug Delivery and Treatment of Neglected Tropical Diseases)
►▼ Show Figures

Graphical abstract

18 pages, 5758 KiB  
Article
Therapeutic Activity of a Topical Formulation Containing 8-Hydroxyquinoline for Cutaneous Leishmaniasis
by Sarah Kymberly Santos de Lima, Ítalo Novaes Cavallone, Dolores Remedios Serrano, Brayan J. Anaya, Aikaterini Lalatsa, Márcia Dalastra Laurenti, João Henrique Ghilardi Lago, Dalete Christine da Silva Souza, Gabriela Pustiglione Marinsek, Beatriz Soares Lopes, Renata de Britto Mari and Luiz Felipe Domingues Passero
Pharmaceutics 2023, 15(11), 2602; https://doi.org/10.3390/pharmaceutics15112602 - 08 Nov 2023
Viewed by 900
Abstract
Cutaneous leishmaniasis exhibits a wide spectrum of clinical manifestations; however, only a limited number of drugs are available and include Glucantime® and amphotericin B, which induce unacceptable side effects in patients, limiting their use. Thus, there is an urgent demand to develop [...] Read more.
Cutaneous leishmaniasis exhibits a wide spectrum of clinical manifestations; however, only a limited number of drugs are available and include Glucantime® and amphotericin B, which induce unacceptable side effects in patients, limiting their use. Thus, there is an urgent demand to develop a treatment for leishmaniasis. Recently, it was demonstrated that 8-hydroxyquinoline (8-HQ) showed significant leishmanicidal effects in vitro and in vivo. Based on that, this work aimed to develop a topical formulation containing 8-HQ and assess its activity in experimental cutaneous leishmaniasis. 8-HQ was formulated using a Beeler base at 1 and 2% and showed an emulsion size with a D50 of 25 and 51.3 µm, respectively, with a shear-thinning rheological behaviour. The creams were able to permeate artificial Strat-M membranes and excised porcine skin without causing any morphological changes in the porcine skin or murine skin tested. In BALB/c mice infected with L. (L.) amazonensis, topical treatment with creams containing 1 or 2% of 8-HQ was found to reduce the parasite burden and lesion size compared to infected controls with comparable efficacy to Glucantime® (50 mg/kg) administered at the site of the cutaneous lesion. In the histological section of the skin from infected controls, a diffuse inflammatory infiltrate with many heavily infected macrophages that were associated with areas of necrosis was observed. On the other hand, animals treated with both creams showed only moderate inflammatory infiltrate, characterised by few infected macrophages, while tissue necrosis was not observed. These histological characteristics in topically treated animals were associated with an increase in the amount of IFN-γ and a reduction in IL-4 levels. The topical use of 8-HQ was active in decreasing tissue parasitism and should therefore be considered an interesting alternative directed to the treatment of leishmaniasis, considering that this type of treatment is non-invasive, painless, and, importantly, does not require hospitalisation, improving patient compliance by allowing the treatment to be conducted. Full article
(This article belongs to the Special Issue Recent Advances in Drug Delivery and Treatment of Neglected Tropical Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop